229 related articles for article (PubMed ID: 33425028)
21. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
[TBL] [Abstract][Full Text] [Related]
23. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
24. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
25. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis.
Nara K; Taguchi S; Buti S; Kawai T; Uemura Y; Yamamoto T; Kume H; Takada T
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458634
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
27. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
28. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
29. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
[TBL] [Abstract][Full Text] [Related]
30. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Xu H; He A; Liu A; Tong W; Cao D
Int Immunopharmacol; 2019 Dec; 77():105957. PubMed ID: 31677498
[TBL] [Abstract][Full Text] [Related]
34. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
35. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
37. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.
Shi Y; Liu X; Liu J; Zhang D; Liu X; Yue Y; Zhou Q; Gao X; Chen M; Xu Y; Zhao J; Zhong W; Provencio M; Jassem J; Williams TM; Seeber A; Kocher F; Wang M
Transl Lung Cancer Res; 2021 Dec; 10(12):4477-4493. PubMed ID: 35070755
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.
Tan K; Wang A; Zheng Y; Wang S; Wang C; Li J; Lu X; Dong H; Zheng J; Cui H
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38922538
[TBL] [Abstract][Full Text] [Related]
39. Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma.
Cao R; Wu C; Lv Y; Xu S; Li C; Yin F; Li J
Oncol Lett; 2023 Feb; 25(2):55. PubMed ID: 36644142
[TBL] [Abstract][Full Text] [Related]
40. Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan.
Hisanaga K; Uchino H; Kakisu N; Miyagi M; Yoshikawa F; Sato G; Isobe K; Kishi K; Homma S; Hirose T
Diabetes Metab Syndr Obes; 2021; 14():773-781. PubMed ID: 33654416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
